ELDN (Eledon Pharmaceuticals) GF Score: 21/100 (As of Jul. 03, 2026) — 40% Below Median


ELDN Eledon Pharmaceuticals Inc ELDN
21 GF Score
Price $3.95
! 2 Warning Signs
View Full Analysis

What is Eledon Pharmaceuticals GF Score?

Eledon Pharmaceuticals ELDN +1.28% 21 GF Score is 21 as of Jul. 03, 2026, which is 40% below its 10-year median of 35.00. GuruFocus rates ELDN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Eledon Pharmaceuticals has the GF Score of 21, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Eledon Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Eledon Pharmaceuticals  (NAS:ELDN) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Eledon Pharmaceuticals GF Score Related Terms

ELDN vs ZNTL, GLSI, SABS: GF Score Comparison

For the Biotechnology subindustry, Eledon Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eledon Pharmaceuticals GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's GF Score falls into.


ELDN
21GF Score
Eledon Pharmaceuticals Inc ELDN
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 21 mean?
Eledon Pharmaceuticals (ELDN) has a GF Score of 21 as of Jul. 03, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Eledon Pharmaceuticals and its competitors. This is 40% below median its historical median of 35.00. Over the past decade, Eledon Pharmaceuticals' GF Score has ranged from 16.00 to 43.00.
Is Eledon Pharmaceuticals' GF Score too high?
Eledon Pharmaceuticals' current GF Score of 21 is 40% below median its 10-year median of 35.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 43.00. Overall, Eledon Pharmaceuticals has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Eledon Pharmaceuticals' GF Score compare to ZNTL and GLSI?
Eledon Pharmaceuticals' GF Score of 21 can be compared against companies in the Biotechnology industry. Historically, Eledon Pharmaceuticals' own GF Score has ranged from 16.00 to 43.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Eledon Pharmaceuticals and its competitors. Eledon Pharmaceuticals's current GF Score is 21, which is 40% below median its own 10-year median of 35.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eledon Pharmaceuticals stock overvalued right now?
Eledon Pharmaceuticals (ELDN) has a current GF Score of 21. The current GF Score is 21, which is 40% below median its 10-year median of 35.00. Eledon Pharmaceuticals' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Eledon Pharmaceuticals (ELDN), the current GF Score is 21 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eledon Pharmaceuticals Business Description

Other Exchanges 2TK:Germany
Address 19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
21GF Score

Get the complete analysis for ELDN

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.95
Price